Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today reported that it had received revised advice from GlaxoSmithKline (GSK) regarding Relenza sales for the December 2008 quarter. The revised sales were A$27.1 million (US$20.8 million) and indicative royalties were A$1.9 million (US$1.46 million). This revision represents an additional A$0.44 million in royalties to Biota.
About Biota Holdings Limited
Contact
Investor / Analyst EnquiriesBiota Holdings Limited
Peter Cook
Tel: +61-3-9915-3720
Damian Lismore
Tel: +61-3-9915-3721
Related Companies
Related Industry Topics: